ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2126

Trial of Atorvastatin for the Primary Prevention of Cardiovascular Events in Patients with Rheumatoid Arthritis

George D. Kitas1, Peter Nightingale2, Jane Armitage3, Naveed Sattar4, Jill Belch5, Deborah P.M. Symmons6 and TRACE RA Consortium, 1Dudley Group NHS Foundation Trust, Dudley, and Arthritis Research Campaign Epidemiology Unit, University of Manchester, Manchester, United Kingdom, 2Wolfson Computer Laboratory, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom, 3Clinical Trial Service Unit and Epidemiology Unit, University of Oxford, Oxford, United Kingdom, 4University of Glasgow, BHF Glasgow Cardiovascular Research Centre, Glasgow, United Kingdom, 5Division of Cardiovascular and Diabetes Medicine, University of Dundee, Dundee, United Kingdom, 6NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Cardiovascular disease, prevention, RCT, rheumatoid arthritis (RA) and statins

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 9, 2015

Title: Rheumatoid Arthritis - Clinical Aspects III - Cardiovascular Disease and RA

Session Type: ACR Concurrent Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose: Patients with rheumatoid arthritis (RA) are at increased risk for cardiovascular disease (CVD) compared to the general population, both due to classical and novel risk factors. It remains unclear whether primary prevention strategies for CVD are effective in high grade inflammatory conditions such as RA and there are no previous, CVD outcome statin trials in patients with RA. TRACE RA was designed to assess whether atorvastatin 40mg daily is superior to placebo for the primary prevention of CVD events in patients with RA.

Methods: Prospective, randomised, double-blind, placebo-controlled, UK multicentre trial in RA patients aged >50 years or RA duration >10 years; without known atherosclerotic disease, diabetes, myopathy; not taking statins. All patients were given lifestyle advice.  Primary endpoint: a composite of CVD death, non-fatal myocardial infarction, cerebrovascular accident (excl. haemorrhagic stroke), transient ischaemic attack, revascularisation. Secondary endpoints included safety outcomes and lipid changes. The trial was designed to have 80% power at p<0.05 to detect a 32% risk reduction with atorvastatin based on 1.8% annual event rate, using intention to treat analysis. Cox regression stratified by centre, Fisher’s exact test, Mann-Whitney test or Kendall’s tau-b were used for analysis, as appropriate.

Results: Trial duration: August 2007-December 2012.  2986 patients from 102 centres were randomised and followed for a median of 2.53 years (IQR 1.94-3.50), providing 7,908 patient-years of follow-up. Atorvastatin and placebo groups did not differ at baseline for age, sex, weight, BMI, RA duration, activity, severity and seropositivity, blood pressure, lipid and glucose levels, family history of CVD or diabetes. Current smoking was higher in the atorvastatin group (18.4% vs 14.5%, p=0.019) and there were also significant differences in NSAID use, ethnicity and EQ5D. Reduction in LDL-c levels was significantly greater in the atorvastatin group compared to placebo (-1.07 vs – 0.14 mmol/l, p<0.001); the magnitude of LDL-c reduction reflected reported compliance. In the atorvastatin group 24 patients had a CVD event, compared to 36 in the placebo (hazard ratio 0.66, 95% confidence interval 0.39-1.11, p=0.119). After adjustment for baseline differences, compliance and non-study statin use, hazard ratio was 0.54 (0.30-0.99), p=0.045.  Number and type of any reported adverse events were similar: 294(19.7%) in the atorvastatin and 292(19.5%) in the placebo group, p=0.927.  Due to a lower (0.76% pa) than anticipated event rate, the trial was terminated early.  

Conclusion: Treatment with Atorvastatin 40mg daily resulted in significantly greater reduction of LDL-c compared to placebo. The 34% (unadjusted) risk reduction for a major CVD event compared to placebo, although not statistically significant due to early termination of the trial, is in line with the Cholesterol Treatment Trialists’ Collaboration meta-analysis of the effect of statins in other populations.  Statin therapy was safe in patients with RA.


Disclosure: G. D. Kitas, None; P. Nightingale, None; J. Armitage, None; N. Sattar, AstraZeneca, Sanofi, Merck, Amgen, 5; J. Belch, None; D. P. M. Symmons, None.

To cite this abstract in AMA style:

Kitas GD, Nightingale P, Armitage J, Sattar N, Belch J, Symmons DPM. Trial of Atorvastatin for the Primary Prevention of Cardiovascular Events in Patients with Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/trial-of-atorvastatin-for-the-primary-prevention-of-cardiovascular-events-in-patients-with-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/trial-of-atorvastatin-for-the-primary-prevention-of-cardiovascular-events-in-patients-with-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology